ANTX (an2therapeutics.com) רווח נקי למניה (EPS TTM)

AN2 Therapeutics, Inc. (ANTX) is expanding its portfolio of treatments for rare pulmonary infections as it pushes toward the commercialization of epetrarobol. The company's rolling annual earnings per share reflects the dynamics of these processes, with the -0.94 metric serving as the target level. Growth is being driven by alliances with medical centers combating resistant bacteria and the implementation of digital clinical data analysis systems.
AN2 Bio (ANTX) - פילוחי מדדים ודוחות פיננסיים

AN2 Therapeutics, Inc. (ANTX) focuses on bringing epetaborole to market for the therapy of rare pulmonary infections. Commercialization costs for the drug directly impact the profit calculation model. This metric measures the rolling year net income distributed per share, excluding the impact of issuance. This allows for an assessment of real capital efficiency without market noise. By analyzing the 12-month net income per share trend, an investor determines the reversal point of the fundamental trend.